Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

SpainBack to Spain

Clinical trials in San Cristobal De La Laguna – page 3

51 clinical trials in San Cristobal De La Laguna, Spain. Every trial is listed in the EU Clinical Trials Register and updated daily.

SpainOur site in SpainEnsayosClinicos.es(opens in a new tab)
San Cristobal De La Laguna at a glance
51
clinical trials
  • Paediatric trials0
  • Research sites0
Type of trial
Recruitment status
Quick filters

51 trials in San Cristobal De La Laguna

Open in trial search

Osteosarcoma+2

Not yet recruiting
Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Trabectedin
  • Sponsor:Instituto De Investigacion Sanitaria Fundacion Jimenez Diaz

Small cell lung cancer limited stage

Not yet recruiting
Investigational
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Sponsor:Pharmacosmos A/S

Asthma

Not yet recruiting
InvestigationalNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Sponsor:Kymera Therapeutics Inc.

Breast cancer+2

Not yet recruiting
Registered drug
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Letrozole
  • Sponsor:Laboratorios Farmaceuticos Rovi S.A.

Mite allergy

Not yet recruiting
Registered drug
Countries:SpainSpain
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Budesonide
  • Sponsor:LETI Pharma S.L.U.

Breast cancer

Not yet recruiting
Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Anastrozole
  • Sponsor:Eli Lilly & Co.

Sjogren's syndrome

Not recruiting
Investigational
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Dazodalibep
  • Sponsor:Horizon Therapeutics Ireland Designated Activity Company

Psoriatic arthropathy

Not recruiting
Registered drug
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Risankizumab
  • Sponsor:MoonLake Immunotherapeutics AG

Small cell lung cancer extensive stage

Not recruiting
Registered drug
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Glucose Monohydrate
  • Sponsor:Pharmacosmos A/S

Arteriosclerosis

Not recruiting
Registered drug
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Inclisiran
  • Sponsor:Novartis Pharma AG

Psoriatic arthropathy

Not recruiting
Investigational
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Zasocitinib
  • Sponsor:Takeda Development Center Americas Inc.

Type 2 diabetes mellitus+1

Not recruiting
Investigational
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:BI 456906
  • Sponsor:Boehringer Ingelheim Espana S.A.

Other cities in Spain

The busiest research cities in the country

All 218 cities in Spain

Clinical research in San Cristobal De La Laguna

What the registry says about research in the country

01 San Cristobal De La Laguna
Eye Diseases
Clinical trials in San Cristóbal de La Laguna are focusing on improving outcomes for patients with Age-Associated Macular Degeneration. Comparative effectiveness of anti‑VEGF agents such as ranibizumab and bevacizumab. Evaluation of genetic polymorphisms influencing drug response. Safety monitoring of emerging ocular therapies. Assessment of visual acuity preservation over a one‑year period. The studies aim to refine therapeutic choices and personalize care for retinal disease.
Immune System Diseases
Researchers are evaluating novel immunomodulators for conditions such as Sjögren’s Syndrome and Psoriatic Arthritis. Systemic symptom relief with targeted cytokine inhibitors. Long‑term safety and tolerability of oral Jak inhibitors. Biomarker‑driven patient stratification for personalized therapy. Impact on quality‑of‑life measures. These trials seek to expand therapeutic options for autoimmune disorders.
Musculoskeletal Diseases
Ongoing work addresses inflammatory joint disease, particularly Psoriatic Arthritis, through emerging biologic treatments. Evaluation of new biologic DMARDs versus standard care. Functional mobility outcomes in treated participants. Safety profile of combination therapy regimens. Patient‑reported pain and fatigue assessments. The goal is to enhance disease control while minimizing adverse effects.
Neoplasms
Oncology studies target small cell lung cancer and multiple myeloma, testing innovative combination regimens. Overall survival benefits of novel agent combinations. Induction therapy optimization for transplant‑ineligible myeloma patients. Safety profiling of antibody‑drug conjugates and targeted therapies. Immunophenotypic response evaluation at 18 months. Efforts aim to improve survival rates and quality of life for cancer patients in the region.
Nutritional and Metabolic Diseases
Trials investigate metabolic health, including management of broad nutritional and metabolic diseases, with a focus on glycemic control. Superiority of immune‑targeting therapy for preserving insulin independence. Metabolic biomarker monitoring throughout study periods. Evaluation of patient‑reported outcomes related to daily functioning. Long‑term safety and tolerability assessments. Researchers hope to identify strategies that reduce disease burden and delay complications.
Virus Diseases
Investigators are conducting antiviral studies for HIV, comparing new oral regimens to established therapies. Non‑inferior viral suppression rates with simplified dosing. Safety and tolerability of the two‑drug regimen. Resistance monitoring in antiretroviral‑naïve participants. Patient adherence and quality‑of‑life evaluation. The aim is to broaden accessible treatment options for treatment‑naïve individuals.
Immune System Phenomena & Processes
Complementary research examines underlying immune mechanisms that drive autoimmune and cancer responses. Characterization of immune phenotypes in trial participants. Analysis of cytokine signaling pathways across disease cohorts. Integration of immunogenomic data to identify predictive biomarkers. Cross‑disease insights informing precision medicine approaches. Insights from these studies may guide targeted therapies across multiple therapeutic areas.
Back to SpainAll countries
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.